Actualités Regencell Bioscience Holdings Ltd - RGC | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF...

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF...

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHE...

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHE...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Annual and Transition Report (foreign Private Issuer) (20-f)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Regencell Bioscience Holdings Ltd (RGC)

Outils de qualité professionnelle, pour des investisseurs individuels.

RGC Actualités

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Amended Statement of Beneficial Ownership (sc 13d/a)

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Amended Statement of Beneficial Ownership (sc 13d/a)

Amended Statement of Beneficial Ownership (sc 13d/a)

Statement of Ownership (sc 13g)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Annual and Transition Report (foreign Private Issuer) (20-f)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Regencell Bioscience Holdings Ltd (RGC) Actualités

Regencell Bioscience Holdings Ltd (RGC)

Outils de qualité professionnelle, pour des investisseurs individuels.

RGC Actualités

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Amended Statement of Beneficial Ownership (sc 13d/a)

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Amended Statement of Beneficial Ownership (sc 13d/a)

Amended Statement of Beneficial Ownership (sc 13d/a)

Statement of Ownership (sc 13g)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Annual and Transition Report (foreign Private Issuer) (20-f)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application